Hôpital Jolimont
- Address
- Rue Ferrer 159, 7100 Haine-Saint-Paul, Belgium
Neoplasms
The Hematology department at Hôpital Jolimont conducts a broad portfolio of cancer studies, ranging from blood‑derived malignancies to solid tumours such as breast, prostate, colorectal, lung, head‑and‑neck and pancreatic cancers. Trials aim to evaluate new targeted agents, combination immunotherapies and innovative radiation techniques to improve survival and quality of life.
- Targeted therapies for Acute Myeloid Leukemia and related myelodysplastic syndromes
- Combination immunotherapy for Diffuse Large B‑Cell Lymphoma
- Novel endocrine agents for HR+/HER2‑negative breast cancer
- Androgen‑targeted strategies in metastatic prostate cancer
- Targeted agents for c‑Met‑overexpressing non‑small cell lung cancer
Across all therapeutic areas, 21 clinical trials are overseen by 18 investigators, reflecting a strong commitment to advancing oncology care in Europe.
Hemic and Lymphatic Diseases
Focused on blood‑related disorders, the site evaluates novel agents and regimens for acute leukaemia, chronic lymphocytic leukaemia, myelodysplastic syndromes and various B‑cell lymphomas. The overarching goal is to enhance response rates, prolong remission and reduce treatment‑related toxicity.
- Evaluating midostaurin plus decitabine in unfit acute myeloid leukaemia
- Assessing ibrutinib with venetoclax in relapsed chronic lymphocytic leukaemia
- Investigating magrolimab combined with chemotherapy in refractory lymphoma
- Studying bispecific antibodies such as mosunetuzumab for B‑cell non‑Hodgkin lymphoma
- Exploring IDH1/2‑targeted combinations in AML and MDS
The department’s expertise in haematology supports a diverse set of trials that address both efficacy and safety of emerging therapies.
Virus Diseases
Research on viral infections includes the emerging mpox outbreak and severe respiratory infections such as hospital‑acquired pneumonia. Studies are designed to test antiviral drugs, immune‑modulating agents and biomarker‑guided treatment strategies to reduce mortality and improve recovery.
- Testing antiviral tecovirimat for mpox virus disease
- Evaluating baricitinib plus standard care for hospital‑acquired pneumonia
- Assessing immune‑modulating therapies in viral‑related respiratory infections
- Monitoring safety of novel antivirals during acute viral outbreaks
- Integrating biomarkers to guide antiviral treatment decisions
These investigations complement the site’s broader oncology program, offering comprehensive care for patients affected by viral pathogens.
Digestive System Diseases
The centre conducts trials on gastrointestinal malignancies, including metastatic colorectal cancer and borderline resectable pancreatic adenocarcinoma. Research efforts focus on combining immunotherapy with chemotherapy, applying advanced radiation techniques and exploring molecularly targeted treatments to extend survival.
- Combining immunotherapy with chemotherapy for metastatic colorectal cancer
- Neoadjuvant approaches for borderline resectable pancreatic adenocarcinoma
- Evaluating stereotactic body radiation for locally advanced gastrointestinal tumors
- Targeting molecular pathways in colorectal and pancreatic cancers
- Assessing quality‑of‑life outcomes in digestive oncology trials
These studies contribute to the site’s multi‑disciplinary strategy for tackling complex digestive system diseases.
Bacterial Infections and Mycoses
In addition to oncology, the hospital addresses serious bacterial infections, notably severe hospital‑acquired pneumonia. Trials aim to evaluate new antimicrobial regimens, anti‑inflammatory adjuncts and diagnostic biomarkers to optimize treatment in critically ill patients.
- Randomized assessment of baricitinib for severe hospital‑acquired pneumonia
- Safety evaluation of novel antimicrobial combinations in critically ill patients
- Biomarker‑driven stratification for bacterial infection therapy
- Exploring adjunctive anti‑inflammatory strategies in bacterial sepsis
- Studying fungal infection prophylaxis in immunocompromised oncology patients
The infection research program works closely with the haematology and oncology teams to protect vulnerable patient populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 5 therapeutic areas and 15 of 66 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 7 by active trials.
- 1AbbVie Deutschland GmbH & Co. KG1active
lock +6 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +2 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hôpital Jolimont
lock Showing 1 of 20 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination With Bevacizumab and FOLFIRI Versus Bevacizumab and FOLFIRI in Previously Treated Advanced Inoperable Metastatic Colorectal Cancer (mCRC) | Gilead Sciences Inc. | Phase II | Not Recruiting | Jun 2023 | Jun 2024 |
IMP list
lock Showing 1 of 66 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Rituximab | 4 | Unknown | 2021-10-14 | 2025-05-16 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.